|
INTRODUCTION
The
commonest
GI
disorder
at
present
is
Irritable
Bowel
Syndrome(IBS).
Though
first
diagnosed
2
centuries
ago IBS
still
remains
poorly
understood
by
physicians
and
patients
around
the
World.
With the
availability
of
better
technique
to study
GI
motility
and
visceral
functions
along
with the
development
of newer
concept
on
importance
of brain
in
regulating
gut
function
significant
progress
has been
made for
better
understanding
of IBS.
Here the
current
knowledge
of IBS
reviewed.
DEFINITION
Functional
bowel
disorder
like IBS
is
defined
as
chronic
,
recurrent
GI tract
disorder
without
any
organic
or
structural
lesion .
Various
studies
have
tried to
define
IBS.
Manning
criteria
(1978),
Rome I
criteria
(1989),
Rome II
criteria
(1998)
were few
studies
to
define
IBS. The
more
acceptable
definition
is Rome
II
criteria.
Rome
II
Criteria
for
diagnosis
of IBS
At least
12
weeks,
which
need not
be
consecutive
in the
preceding
12
months
of
abdominal
discomfort
or pain
that has
2 of the
following
3
features
1.
Relieved
by
defecation
2.
Onset
associated
with
change
in stool
frequency
3.
Onset
associated
with
changes
in stool
pain
PREVALENCE
AND
EPIDEMIOLOGY
Prevalent
Worldwide
affecting
4% to
35%
adults,
common
in woman
than
man.
Woman
make up
80% of
population
with
severe
IBS. In
most
patients
the
symptoms
starts
in late
teenage
or early
20s, (3rd
and 4th
decade)
and
decreases
in 6th
and 7th
decades.
After 60
years
diagnosis
of IBS
is to be
differentiated
from
other
diseases
like
colon
cancer
and
diverticulitis.
PATHOPHYSIOLOGY
A
connection
between
brain
and gut
was
proposed
by Almy
and
Mullin
by
observing
colonic
motility
changes
related
to
stressful
information.
IBS is a
complex
disorder
in which
various
physiologic
process
are
involved
, like
abnormalities
of
intestinal
motility,
alteration
of
visceral
sensory
function
,
changes
in CNS
processing
of
sensory
information’s,
psychological
stress
and
luminal
factors.
Interplay
between
gut and
CNS has
been
called
as Brain
–Gut
axis
1.
Altered
gut
motility
motor
activity
In IBS
patients
antroduodenal
manometry
study
shows
discrete
clustered
contraction
of small
intestine.
These
are
bursts
of
rhythmic
contractions
and
associated
with
abdominal
pain. In
other
very
prolonged
contractions
are seen
within
colon or
small
intestine
or very
high
amplitude
propagating
contractions
within
the
colon,
more in
postprandial
period
with
episodic
abdominal
pain.
Alteration
of
migratory
motor
complex
may
either
delay
(constipation
) or
accelerate
(diarrhoea)
intestinal
transit
. It
reflects
the
exaggeration
of
normal
GI
motility
pattern.
The
motility
pattern
differs
in
different
patients.
Colonic
myoelectrical
& motor
activity
studies
shows
abnormalities
under
stressful
conditions
in IBS.
They may
exhibit
increased
rectosigmoid
motor
activity
upto 3
hours
after
eating.
Provocative
stimuli
like
inflation
of
rectal
balloon
may lead
to
distention
evoked
contractile
activity.
Recording
from
transverse
descending
,
sigmoid
colon
show
high
amplitude
of
motility
index
and peak
amplitude
in
diarrhea
prone
IBS.
2.
Enhanced
Visceral
Sensitivity:
Abdominal
pain is
a
critical
part of
the
criteria,
the
cause of
which is
not yet
established.
It has
been
demonstrated
that
there
occurs
an
increased
sensitivity
to pain
within
GI tract
(by
balloon
inflation
study at
various
level in
GI
tract).Exhibit
exaggerated
sensory
response
to
visceral
stimuli,
postprandial
pain is
related
to entry
of food
to
caecum
in 74%.
The
visceral
hyperalgesia
appears
to be
selective
for
mechano-receptor
activated
stimuli
as
perception
of
intestinal
mucosal
electrical
stimulation
is
normal
in IBS.
Lipids
lower
the
threshold
for the
first
sensation
of gas,
discomfort
and pain
in IBS.
The area
of
referred
pain
after
lipid
ingestion
is
increased.
So
postprandial
symptoms
are
explained
by a
nutrient
dependant
exaggerated
sensory
components
of
gastrocolonic
response.
IBS
patients
don’t
exhibit
increased
hypersensitivity
anywhere
in body.
So
disturbance
is
selective
to
visceral
innervations
rather
than
somatic.
The
increased
response
may be
due to
(a)
Increased
endorgan
sensitivity
with
recruitment
of
silent
nociceptors.
(b)
Spinal
hyperexcitability
with
activation
nitric
oxide
and
other
neurotransmitters.(c)
Endogeneous
(cortical
and
brain
stem)
modulation
of
caudad
nociceptive
transmission.Development
of long
term
hyperalgesia
due to
neuroplasticity
resulting
in
permanent
or
semipermanent
changes
in
neural
response
to
chronic
or
recurrent
visceral
stimulation.
3.
Influence
of CNS
-
In
patients
of
IBS
sensory
processing
is
altered
outside
GI
tract.
It
has
proved
by
various
studies.
- Positron emission tomography scanning of CNS during ballon distention in IBS patients showed increased activity in prefrontal area associated with anxiety , hypervigilence and reduced activity in anterior cingulate cortex an area important for opioid binding. IBS patients exhibit no increased blood flow in the anterior cingulate gyrus but show activation of the prefrontal cortex in response to rectal activation or rectal distention. Activation of frontal lobe may activate a vigilance network and alertness. The anterior cingulate cortex and prefrontal cortex have a reciprocal inhibitory effect. Thus in IBS the preferential activation of prefrontal lobe without activation of anterior cingulate cortex may represent a form of cerebral dysfunction leading to increased visceral pain perception.
- Functional MRI also showed different CNS activity in IBS patients.
·
These
studies
suggest
that IBS
patients
may
process
sensory
information
from GI
tract
differently
than non
IBS.
Besides
other,
stimuli
like
stress,
anxiety,
depression
may
modulate
sensory
processing
and
influence
the
perception
of pain.
4.
Other
factors
(a)
Infection
–
Infectious
gastroenteritis
may
increase
the like
hood of
IBS in
later
life.
The
mechanism
of post
infectious
IBS may
be due
to (i)
Transient
or
permanent
damage
of
enteric
nervous
system,
the
intrinsic
nerve
supply
responsible
for
coordinating
GI
peristalsis.
(ii)
Development
of
immune
hypersensitivity
in which
repeated
exposure
to
benign
substance
induces
inflammation
and
altered
motility.
(iii)
Infectious
agent
initiates
a cycle
of
chronic
mucosal
inflammation
leading
to
altered
gut
motility.
Common
in women
and
younger
patients.
Microbes
involved
are
Campylobacter,
Salmonella,
Shigella
Increased
rectal
endocrine
cells, T
–
Lymphocytes
and gut
permeability
are
acute
changes
following
Campylobacter
which
contributes
to post
infective
IBS.
(b)Role
of
physical
and
sexual
abuse
Several
studies
have
shown
higher
incidence
in
physical
and
sexual
abuse
cases
specially
in
woman.
Forms of
sexual
abuse
includes
verbal
aggression,
exhibitionism,
sexual
harassment,
sexual
touching,
rape.
The
pathophysiology
is
unknown
and pain
threshold
is not
lowered.
(c)
Psychiatric
factor
Recorded
in 80%
cases of
IBS. No
single
psychiatrics
diagnosis
associated.
Most
patient
demonstrate
exaggerated
symptoms
.
Influences
pain
threshold,
stress
alters
sensory
threshold.
(d)
Hormonal
Serotonin
(5HT)
containing
enterochromaffin
cells in
the
colon
and
postprandial
plasma
5HT are
increased
in
Diarrhoea
predominant
IBS. As
5 HT
plays
important
role in
GI
motility
they are
responsible
for
pathogenesis
and
treatment
by 5 HT
antagonist.
DIAGNOSIS
With a
through
interview
and
physical
examination
IBS can
be
diagnosed
at the
first
visit.
Physicians
should
not down
play the
symptoms
on the
ground
that
they
exist in
patients
mind.
Because
physiologically
and
therapeutically
definite
GI
motility
and
visceral
sensation
abnormalities
exist in
IBS
patients.
The
accuracy
of
diagnosis
may be
97% by
proper
evaluation
of
symptoms
, normal
physical
examination
and
normal
simple
laboratory
test.
Diagnosis
on basis
if Rome
II
criteria
in
practically
less
useful
for its
restrictive
nature.
Currently
American
College
of
Gastroenterology
recommends
the
broad
definition
for
clinicians-
Abdominal
pain or
discomfort
associated
with
altered
bowel
habit
and
absence
of
warning
signs or
“red
flags”
suggestive
of
organic
disease.
SYMPTOMS
The
pattern
of
symptoms
(abdominal
pain ,
altered
bowel
habit)
varies
from
person
to
person
but
remain
consistent
in same
individual
varying
in
intensity
and
frequency.
Typically
symptoms
are
intermittent
with
symptom-free
period
lasting
for days
, weeks
or
months.
Rarely
patients
have
daily
symptoms.
A.
Abdominal
pain
Hallmark
of IBS.
Duration
– for at
least 12
weeks
during
preceding
12
months
(need
not be
consecutive)
or more
than 25%
of time
during
preceding
3
months.
Related
to
defecations
anyway .
Intensity
quality
– Varies
among
patients
but
remains
stable
for
individual
patients.
Described
as
crampy
or sharp
or
burning
May be
episodic
with a
background
of
consistent
for
individual.
Location:Hypogastium
(25%),
right
side
(20%),
left
side
(20%)
and
epigastrium
(10%) .
Pain may
be mild
to be
ignored
or
interfere
daily
activities.
Malnutrition
due to
inadequate
coloric
intake
is rare.
Sleep
deprivation
is rare
as it
occurs
in day
and
waking
hours.
In
severe
IBS may
be
associated
nocturnal
pain
with
poor
prognosis.
Pain
often
exacerbated
by food
or
stress
and
relieved
by
passage
of stool
or
flatus.
Females
have
worsening
of
symptoms
during
premenstrual
and
menstrual
cycle.
B. Bowel
habit
Normal
bowel
movement
ranges
from 3
per week
to 3 per
day.
The
altered
bowel
habit
varies
in
patients
but
remains
consistent
for
individual.
Three
patterns
are
observed
–
Diarrhoea,
constipation
or
alternating
diarrhoea
and
constipation
(most
common).
Patients
having
diarrhoea
usually
have
normal
consistency
is
morning
but
subsequent
bowel
movement
becomes
loose
associated
with
urgency,
abdominal
cramp,
flatulence
and
sense of
incomplete
evacuation.
Stools
become
more
liquid
associated
with
mucous
and
feeling
of
drained
out.
Small
volumes
of loose
stool (<
200 ml).
Nocturnal
diarrhoea
does not
occur in
IBS.
Diarrhoea
is
aggravated
by food
or
stress.
May be
associated
with
large
amount
of
mucous.
Bleeding
is not
usually
unless
associated
haemorrhoid
and
malabsorption
and
weight
loss do
not
occur.
Patients
with
constipation
complains
of rocky
hard
stool
(scybala)
associated
with
straining
and
incomplete
evacuation
and
associated
mucous .
Initially
may be
episodic
eventually
becomes
continuous
and
gradually
intractable
to
laxative
treatment.
C. Fecal
incontinence
Staining
of
undergarments
occurs
in 20%
of IBS.
More
marked
in cases
of IBS
with
diarrhoea
or
diarrhoea
alternating
with
constipation.
May be
due to
repetitive
relaxation
of
sphincter
muscles
with
repetitive
colonic
spasm.
D.
Bloating
and
abdominal
distention
(Gas &
Flatulence)
Very
common
and due
to
increased
abdominal
gas or
increased
sensitivity
of gut
to
normal
gas.
Some
patients
of IBS
has
aerophagia,
and
increased
belching
and
flatulence.
Though
increase
in gas
is
complained
intestinal
gas
amount
is
normal.
IBS has
impaired
transit
and
tolerance
of
intestinal
gas and
tendency
to
reflux
gas from
distal
to
proximal.
E. Other
constitutional
symptoms
1.
Weight
loss –
No
weight
loss
(if
weight
loss
question
about
warning
or “Red
flag “
sign)
2.
Anaemia
/GI
bleeding
/Stool
occult
blood –
Unusual
3.
Fatigue,
myalgia,
arthralgia,
fever,
chill,
night
sweat –
rare
F. Upper
GI
symptoms
25 to
50% of
IBS
complain
dyspepsia,
heart
burn,
nausea
and
vomiting.
Overlap
between
IBS and
dyspepsiaoccurs
. In IBS
case 55
%
complain
dyspepsia
and in
dysopeptic
patients
31.7%
have
IBS.
This
functional
disorder
may
fluctuate
and
indicate
a single
,
extensive
G.I
disorder.
IBS are
more
prevalent
in
patients
having
noncardiac
chest
pain.
PHYSICAL
EXAMINATION
Thorough
physical
examination
is
needed
to
exclude
any
associated
disease
or make
a second
diagnosis.
Generally
the
physical
examinations
are
normal.
P/A
examination
shows
some
tenderness
due to
visceral
hypersensitivity
, rectal
spasm
and
muscular
contraction.
Any
significant
mass,
tenderness
or
bleeding
warrants
other
causes.
Suggestive
features
of IBS
include
recurrence
of
abdominal
pain
with
altered
bowel
habit
over a
period
of time
without
progressive
deterioration,
onset of
symptoms
during
stress
or
emotional
upset,
without
any
systemic
symptoms
like
fever,
weight
loss and
small
volume
of stool
without
evidence
of
blood.
On the
other
hand the
disorder
appearing
first
time in
old age
, with a
progressive
course
from
onset ,
persistent
diarrhoea
after 48
hr fast,
nocturnal
diarrhoea,
steatorrhoea
excludes
IBS.
DIFFERENTIAL
DIAGNOSIS
As per
the
triad of
symptoms
in IBS
the list
of D/D
is long.
a)
Quality,
location
, timing
of pain
may help
for
specific
disease.
Pain in
epigastric
&
periumbilical
–
biliary
tract
disease,
peptic
ulcer,
intestinal
ischaemia,
Ca
stomach
and
pancrease.
Postprandial
pain
with
nausea,
bloating
–
gastroparesis,
partial
intestinal
obstruction,
giardia
and
other
parasite
infestation.
b)
Diarrhoea
–
Lactase
deficiency,
lexative
abuse,
malabsorption,
hyperthyroidism
,
inflammatory
bowel
disease,
infectious
diarrhoea.
c)
Constipation
– Side
effects
of drugs
like
anticholinergics
,
antihypertensives
and
antidepressants,
hypothyroidism
and
other
endocrinopathies
. Acute
intermittent
porphyria
and lead
poisoning.
INVESTIGATION
The goal
is to:
establish
early
diagnosis,
find
co-existing
and
alternative
diagnosis,
avoid
unnecessary
procedures.
Certain
guidelines
have
been
delineated
for
diagnosis
evaluation.
They
include
duration
of
symptoms
, the
change
in
symptoms
over
time ,
age and
sex,
referral
status
of the
patient,
prior
diagnosis
studies,
family
history
of
colorectal
malignancy,
psychosocial
dysfunction.
Laboratory
features
that
argues
against
IBS are
–
evidence
of
anaemia,
raised
ESR,
leucocytes
or RBC
in
stool,
stool
volume >
200 to
300
ml/d.
Although
extensive
tests
were
followed
in the
past but
it is
now
recognized
that no
test is
necessary
in
younger
patients
who meet
the
criteria
of IBS
and have
normal
clinical
findings
without
‘red
flag’
signs.
But in
the era
of
medical
malpractice
objective
tests
are
necessary.
A
complete
blood
count,
measuring
ESR and
C-reactive
protein
level is
necessary
if it is
recent .
If
constipation
is
predominant
estimate
thyroid
function
test .
If
diarrhoea
predominant
–stool
is
tested
for
leucocytes
and
subjected
to
culture
and
examine
for ova
or
parasites.
Stool
should
be
tested
for
Clostridium
difficile.
If
persistent
diarrhoea-serological
test to
exclude
Celiac
disease
because
incidence
of
celiac
disease
is 10
times
more in
IBS than
normal.
Flexible
sigmoidoscopy
– in
young (<
40
years)
having
altered
bowel
habit,
rectal
discomfort.
Colonoscopy
– In age
above 50
years ,
having
family
history
of
inflammatory
bowel
disease,
colorectal
cancer
or
anaemia.
Upper GI
endoscopy,
oesophagogastroduedenoscopyy,
ultrasonogram
may be
done to
rule out
other
causes.
TREATMENT
General
Principles
:
primarily
focused
on
symptomatic
relief
through
various
modalities
like
patient
education
and
reassurance,
diet ,
supportive
and
behavioral
therapy
and
pharmacotherapy.
Successful
management
requires
physicians
understanding
and
patients
knowledge
and
confidence.
Chronic
nature
of the
disease
requires
prolonged
cooperative
endeavor
on the
part of
physician
and
patient.
Treatment
starts
at first
visit of
the
patient
when the
patient
develops
care and
confidence
on
physician
in way
of
meticulous
interview
and
thorough
physical
examination.
Contributing
factors
like
diet ,
emotional
state
professional
and
interpersonal
relationship
and fear
and
concern
are to
be
considered.
Patient
is to be
explained
the
pathophysiology,
influencing
factors,
chronicity
of the
disease.
DIET
Though
many
patients
attribute
to food
allergy,
true
food
allergy
is
uncommon
in IBS.
The act
of
eating
may
precipitate
bloating,
gas or
abdominal
discomfort.
Some
patients
may
relate
the
symptoms
to some
specific
diets
which
are to
be
avoided
if the
symptoms
recur on
at least
2
occasions
of
stopping
and
reintoduction
of the
diet.
The
commonest
genetic
disorder
Lactase
insufficiency
may be
associated
with
IBS.
This can
be
established
by
inducing
symptoms
following
milk
drink or
relief
of
symptoms
by
giving
lactose
free
diet.
PHARMACOTHERAPY
Due
to
complex
pathophysiology
no
single
agent
has been
able to
cure
IBS.
Treatment
is
targeted
at
relieving
individual
symptoms.
However
FDA has
approved
2 drugs
which
relieves
multiple
symptoms.
(a)
Tegaserod
–
Relieves
global
symptoms
of IBS
with
constipation
(Pain ,
bloating,
discomfort
&
constipation).
(b)
Alosetron
–
Relieves
global
symptoms
of IBS
with
diarrhoea.
I.
CONSTIPATION
1.
For
patients
of mild
symptoms:
life
style
modification,
change
in diet,
use of
fibre
supplement,
daily
fluid
intake
minimum
64 OZ,
food
with
natural
fibres,
use
bathroom
at a set
time are
to be
tried.
2.
If this
is
effective
fiber
supplementation
like :
I)
Methylcellulose,
psyllium
ii)
Polycarbophil,
coarse
bran
iii)
Ispaghula
husk are
used
.These
products
are
hydrophilic
agents
binding
water
and
prevent
dehydration
. Only
three
studies
have
been
significant
1 for
polycarbophil
and 2
for
ispaghula
husk.
These
agents
produce
bloating
and
distention
in 30%
cases.
Magnesium
hydroxide
(Tab ,
Liq) may
be used
for
constipation
, though
does not
relive
abdominal
pain and
bloating.
Long
term
magnesium
is
harmful
in renal
insufficiency.
Recently
fiber
supplementation
with
psyllium
has been
shown to
reduce
perception
of
rectal
distention,
indicating
that
fiber
may have
a
positive
affect
on
visceral
afferent
function.
Beneficial
effect
of
fibers
on
colonic
physiology
suggest
an
effective
treatment
though
results
of
various
trials
are
variable.
Most
investigations
report
increase
in stool
weight,
decrease
in
colonic
transit
time ,
improvement
of
constipation.
A
crossover
comparison
of
different
fiber
preparations
found
that
psyllium
produced
greater
improvement
in stool
pattern
and
abdominal
pain
than
bran.
Psyllium
produces
less
bloating
and
distention.
Despite
equivocal
data
regarding
efficacy
stool
bulking
agents
are
worth
trying
in IBS.
3.
Medication
includes
(a)
Lactulose
(b)
Polyethylene
glycol
(c)
Prostagladin
agents –
misoprostol
(d)
Colchicine
(e)
Tegaserod
(5HT4
agonist
).
Tegaserod
-
Stimulates
prokinetic
activity
by
stimulating
peristalsis.
In
constipation
tegaserod
accelerates
intestinal
and
ascending
colon
transit.
It
selectively
binds to
serotonin
type 4
(5 HT4)
receptors
in the
gut and
directly
initiates
peristalsis.
It
relieves
constipation,
accelerates
orocaecal
transit,
bloating
and
abdominal
pain in
2/3rd
patients.
It is
recommended
as Grade
A drug
for
relieving
global
symptoms.
Side
effects
is
diarrhoea
and
ischaemic
colitis.
Table –
1
Selected
medications
used for
constipation
in
Irritable
Bowel
Syndrome
|
Drug |
Dosing |
Common side effects |
Comments |
|
Fiber products |
Coarse bran
Ispaghula husk
Methylcellulose
Polycarbophil
Psyllium |
1-2tsp/d; advance as tolerated
20g/d
0.5-1 T (1-2g) qd-tid
625 mg qd-tid
3.4 g qd-tid |
Bloating, abdominal distention |
Anecdotal; few controlled trials |
|
Osmotic agents |
Lactulose
Polyethylene glycol |
15-30ml (10-20)qd-tid
17g/d |
Bloating, cramps, flatulence |
|
|
5 HT4 agonist |
Tegaserod |
6 mg bid ac for 4-6 wk; if response positive, can consider additional 4-6 wk |
Headache, diarrhoea |
Grade A recommendation by ACG; warning issued in April 2004 about potential for serious consequence of diarrhoea and a precaution for rare, ischemic colitis |
|
Others |
Colchicine
Magnesium hydroxide |
0.6mg/d
622-1, 244 mg qd-qid |
Nausea, vomiting, diarrhoea, abdominal pain
Diarrhoea, cramps
|
May worsen symptoms in some patients , long term safety unknown
Mild constipation only; avoid long term use in patients with renal insufficiency |
II.
DIARRHOEA
Peripherally
acting
opiate
based
agents
are the
initial
therapy
of
choice
in
diarrhoea
predominant
IBS.
Physiologically
they
produce
increase
in
segmenting
colonic
contraction,
delay in
faecal
transit,
increase
in anal
pressure
and
decrease
in
rectal
perception.
They are
most
useful
when
taken
before
anticipated
stressful
events.
The use
of
antidiarrhoeal
should
be
considered
as
temporary
management,
with a
final
aim of
gradual
withdrawal
of drug
with
substitution
of high
fiber
diet .
Medication
are
Diphenoxylate
HCL –
Atropine,
Loperamide
– By
increasing
gut
transit
time it
allows
more
fluid
absorption.
By
increasing
external
anal
sphincter
tone
decreases
incontinence
and
soiling,
Tricyclic
antidepressants
(TCA) –
in low
doses
decrease
frequency
,
Calcium
channel
blockers
–
decrease
motility
in some
cases,
Deodorized
tincture
of opium
(DTO),
Alosetron
– A 5 HT3
receptor
antagonist.
Alosetrin
:
Evaluated
in
diarrhoea
predominant
IBS.
Serotonin
acting
on 5HT3
receptor
enhances
the
sensitivity
of
afferent
neurons
projecting
from
gut.
Alosetron
, the
drug
reduces
painful
visceral
sensation,
induces
rectal
relaxation
,
increases
rectal
compliance,
delay
colonic
transit
time,
improves
stool
frequency,
consistency
and
urgency.
Women
respond
better
than
man.
However
due to
sideeffect
like
ischaemic
colitis
the drug
has been
withdrawn.
Newer
5HT3
receptor
antagonist
Cilansetron
have
same
effect
as
alosetron,
but
needs
further
follow
up
trial.
Table –
2
Selected
medications
used for
Diarrhoea
in
Irritable
Bowel
Syndrome
|
Drug |
Dosing |
Common side effects |
Comments |
Antidiarrheals
|
Diphenoxylate
HCL –atropine
Leperamide |
5 mg tid-qid
2-4 mg qid, up to 16mg/d |
· Bloating constipation, loss of appetite , abdominal pain, nausea, vomiting
· Abdominal pain and distention, constipation , dry mouth, nausea, vomiting |
Discontinue as soon as diarrhoea is controlled |
Resin-binding agent
|
Cholestyramine |
4 g qd-bid |
Constipation , flatulence , can decrease absorption of other drugs |
|
Opioid
|
DTO |
0.6ml qid , upto 2.4 ml/d |
Sedation , constipation |
Do not confuse with paregoric – DTO contains 25 mins more morphine than paregoric |
5HT3 antagonist
|
Alosetron |
1 mg qd for 4 wk; if tolerated can be increased t 1 mg bid |
Constipation |
Grade A recommendation by ACG; discontinue immediately if constipation or signs of ischemic colitis develop; limited use program , efficacy not established in men. |
Others
|
TCAs: amoxapine
amitriptyline
| |